Abstract: Objective To analyze the clinical efficacy and safety of Terlipressin in treatment of hepatorenal
syndrome (HRS) from the aspect of evidence-based medicine in order to provide medical evidence for
clinical application. Methods Terlipressin and hepatorenal syndrome were retrieved in CNKI, Wanfang Data,
PubMed, CBM, Embase, CCTR and Medline, the retrieval time was up to January 2016. Cochrane system
evaluation method was used to evaluate the papers which were conformed to the selection criteria. Meta-
analysis was carried out by Review Manger 6.0 software. Results Total of 4 English randomized comparison
clinical trial (RCT) articles out of 51 retrieved papers were conformed to the selection criteria, which included
234 patients with HRS. According to the Cochrane quality evaluation criteria, the 4 RCT articles were all
class B. Meta-analysis showed that the efficacy of terlipressin in patients with HRS was statistically different
from that of the control group (OR = 6.85, 95%CI: 3.47～13.55, P ＜ 0.00001). There was no significant
publication bias in Meta-analysis and the results were stable. Part of the HRS patients treated with terlipressin
showed adverse reactions, but they were well tolerated and usually relieved by themselves, and some serious
adverse reactions were effectively relieved after symptomatic intervention. Conclusions Terlipressin can
significantly increase the survival rate of patients with HRS. It can also decrease the creatinine levels, increase
the urine output, improve the renal function and has good efficacy and safety.